Renhong Tang

机构：National Medical Products Administration, Simcere Pharmaceutical (China), Taiwan Semiconductor Manufacturing Company (China)

发表论文 75 篇 · 总被引 982 次 · h-index 14

代表论文

• Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir (2023 · Nature Communications · 被引 114)
• Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19 (2024 · New England Journal of Medicine · 被引 108)
• Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke (2024 · JAMA Neurology · 被引 96)
• A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects (2023 · European Journal of Pharmaceutical Sciences · 被引 26)
• SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models (2023 · Breast Cancer Research · 被引 11)
• SCR‐7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the S ‐adenosylmethionine‐competitive or the methylthioadenosine‐cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase‐deleted tumors (2024 · MedComm · 被引 10)